Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 5Genitourinary 4Breast 4Gynecologic 3Tumor-Agnostic 2Sarcoma 2Myeloid 2Lymphoid 2Head & Neck 2Thoracic 1Plasma cell 1Other hematologic neoplasm 1Dermatologic 1Classical hematology 1CNS 1

Conditions

Neoplasm Metastasis 2Neoplasms 1

Interventions

pembrolizumab 34Specimen Handling 26Magnetic Resonance Spectroscopy 26Radiosurgery 25Biopsy 25Gemcitabine 22Nivolumab 21Paclitaxel 18Carboplatin 16Bevacizumab 15Trastuzumab 14Everolimus 12Radiotherapy 11Irinotecan 11trastuzumab deruxtecan 10atezolizumab 10Erlotinib Hydrochloride 10Docetaxel 10Cetuximab 10Capecitabine 10Albumin-Bound Paclitaxel 10130-nm albumin-bound paclitaxel 10Sorafenib 9Ipilimumab 9Cisplatin 9Taxes 8Standard of Care 8Oxaliplatin 8Drug Therapy 8olaparib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasm Metastasis × Immunoglobulin G × Tumor-Agnostic × Clear all
NCT03842228 2026-05-29

COD

National Cancer Institute (NCI)

Phase 1 Active not recruiting
39 enrolled 15 charts
Tumor-Agnostic

Neoplasm Metastasis

NCT03907475 2026-05-13

Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial

National Cancer Institute (NCI)

Phase 2 Recruiting
115 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡